Publikationen und Vorträge
Dr Katja Schindler Publikationen


ryptogenic organizing pneumonia due to amiodarone: long-term follow-up after corticosteroid treatment. Schindler K, Schima W, Kaliman JF.; Wien Klin Wochenschr. 2010

A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. Schindler K, Schicher N, Kunstfeld R, Pehamberger H, Toepker M, Haitel A, Hoeller C, Harmankaya K; Melanoma Res. 2012

Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. Schicher N, Edelhauser G, Harmankaya K, Schindler K, Gleiss A, Pehamberger H, Hoeller C.; J Eur Acad Dermatol Venereol. 2012

Current options and future directions in the systemic treatment of metastatic melanoma. Schindler K., Postow M.A.; J of Community and Supportive Oncology. 2014

Incidence and risk of xerosis with targeted anticancer therapies. Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S., Lacouture ME; J Am Acad Dermatol. 2015

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Chan A. Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME.; Support Care Cancer. 2015

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, Delord JP, Lacouture ME; Breast Cancer Res Treat. 2014

Kutane Nebenwirkungen onkologischer Therapien - Herausforderung und Chance

Schindler K, Hautnah 2015

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD; Ann Oncol. 2015

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?  Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM; PLoS One. 2015

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Drilon A, Eaton A, Schindler K, Gounder M,2, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM; Cancer. 2016

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal N7, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME; Cancer Immunol Res. 2016

What does the future hold for immunotherapy in cancer? Naidoo J, Li B, Schindler K, Page DB; Ann Transl Med. 2016

Kongressvorträge und Abstracts

GDV Linz 2011: Five year experience in the treatment with anti CTLA-4 antibodies at the Skin Cancer Center of the Department of Dermatology, Medical University of Vienna. Schindler K., Harmankaya K, Schicher N., Binder M., Hoeller Ch., Pehamberger H.

EADV Prague 2011: An exceedingly rare case of primary rhabdoid melanoma of the urinary bladder.  Schindler K.,  Kunstfeld R., Pehamberger H. and Harmankaya K.

OGDV Linz 2012: The development of dermatologic adverse events under therapy with Sunitinib in patients with mRCC correlates to improved progression free and overall survival. Harmankaya K., Hoelzel R., Schindler K., Schicher N., Frantal S., Schmidinger M.

OGDV Linz 2012: Clinical Effect and side effects of the B-raf Inhibitor Vemurafenib  - Single Center Experience of the Skin Cancer Center of the University Clinic of  Dermatology Vienna. Schindler K., Harmankaya K, Schicher N., Silmbrod R., Pehamberger H.,Hoeller Ch

ADO Hannover 2012: Discrepancy between Staging according to m-WHO/RECIST versus immune-related Response Criteria on patients under anti- CTLA-4 antibody treatment. Harmankaya K., Schindler K., Schicher N., Silmbrod R., Pehamberger H., Hoeller Ch.

ADO Hannover 2012: DRESS-Syndrome under therapy with the B-raf Inhibitor Vemurafenib. Schindler K., Schicher N.,  Harmanakaya K., Wimmer N., Pehamberger H., Hoeller Ch.

ASCO Chicago 2013: Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival? Mangana J., Goldinger S.M., Schindler K., Rozati S., Frauchiger A.L., Rechsteiner M., Moch H., Romano E., Kaehler K.C., Michielin O., Hauschild A., Hoeller C, Dummer R.

ASCO Chicago 2013: Pretreatment levels of absolute and relative eosinophil count improve overall survival (OS) in patients with metastatic melanoma under treatment with Ipilimumab, an anti CTLA-4 antibody. Schindler K., Harmankaya K, Postow M.A., Frantal S., Bello D., Ariyan C.E., Michielin O.A., Hoeller C., Pehamberger H., Wolchok J.D.

ASCO Chicago 2014: Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. Schindler K., Harmankaya K., Kuk D. , Mangana J., Michielin O., Hoeller C., Dummer R., Pehamberger H., Wolchok J.D.,  Postow M.A.

ASCO Chicago 2014: Clinical and histologic characterization of dermatologic adverse events from the pan-PI3K inhibitor buparlisib (BKM-120) Schindler K., Abraham R., Shah P., Chandarlapaty S., Paik P., Bell-McGuinn K., Bajorin D., Mellinghoff I., Younes A., Gounder M., Fury M., Busam K., Dickler M., Lacouture M

ÖGDV Vienna 2014: Cutaneous side effects of new oncologic treatments. Schindler K.

ÖGDV Vienna:  Anti PD-1 antibodies for treatment of metastatic melanoma – Single Center Experience of the Skin Cancer Center of the University Clinic of Dermatology Vienna Schindler K.